PERSON – Page 25

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

6 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy

Dr. Reddy’s Recalls Over 300,000 Bottles of Thyroid Medication Due to Carcinogen Contamination

6 months ago talkbio0Tagged adulteration, Carcinogens, Dr. Reddy 's, pharmaceutical safety, regulatory, Thyroid preparations, United States Food and Drug Administration

Dr. Reddy’s, thyroid drug recall, carcinogen contamination, pharmaceutical safety, FDA regulations

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

6 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.

Novo Nordisk Secures $285 Million Biobucks Deal with Ascendis Pharma for Monthly GLP-1 Agonist Development

6 months ago talkbio0Tagged Agonist, Ascendis, biobucks, Drug Development, Glucagon-Like Peptide 1, Nordisk, Pharma

Novo Nordisk, Ascendis Pharma, GLP-1 agonist, biobucks deal, pharmaceutical development

ESSA Pharma Terminates Masofaniten Development After Phase 2 Trial Failure in Prostate Cancer

6 months ago talkbio0Tagged Clinical Trial Termination, enzalutamide, ESSA, Malignant neoplasm of prostate, masofaniten, Pharma, Phase 2 trial

ESSA Pharma, Masofaniten, Prostate Cancer, Phase 2 Trial, Enzalutamide, Xtandi, Clinical Trial Termination

AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology

6 months ago talkbio0Tagged AbbVie, Biological Factors, EvolveImmune, Immunotherapy, Next-Generation Cancer, Oncology Collaboration, T-Cell Engager Technology, Tumor cells, malignant

AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies